Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | DRD1 | P21728 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2231802 | 0.87 | MAPT (0.41) | ALDH1A1NPSR1MAPTHTTSMN1; SMN2 | |
| SCHEMBL2233257 | 0.79 | ALDH1A1 (0.32) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL1012642 | 0.79 | MEN1 (0.34) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL1010853 | 0.79 | ALDH1A1 (0.32) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL15069120 | 0.78 | KDM4E (0.31) | ALDH1A1KDM4E | |
| SCHEMBL10029427 | 0.77 | HRH3 (0.37) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL2231171 | 0.77 | HRH3 (0.31) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL14776843 | 0.77 | HRH3 (0.30) | HRH3 | |
| SCHEMBL21562371 | 0.75 | ALDH1A1 (0.36) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL14246510 | 0.75 | ALDH1A1 (0.40) | ALDH1A1NPSR1POLBMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372844-B1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2011-01-05 | — | — | EP | claimed |
| EP-1372844-A4 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INST OF TECHN (US) | 2005-10-12 | — | — | EP | claimed |
| US-6838489-B2 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | CYMETECH, LLC (US) | 2005-01-04 | — | — | US | claimed |
| EP-1372844-A1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | California Institute of Technology (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2003097562-A2 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2003-11-27 | — | — | WO | claimed |
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-07-31 | — | — | US | claimed |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-05-01 | — | — | US | claimed |
| WO-2002076613-A1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-03 | — | — | WO | claimed |
| US-9006336-B2 | Curable polysiloxane coating composition | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2838935-A1 | CURABLE POLYSILOXANE COATING COMPOSITION | 3M Innovative Properties Company (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20140378608-A1 | CURABLE POLYSILOXANE COATING COMPOSITION | 3M INNOVATIVE PROPERTIES COMPANY | 2014-12-25 | — | — | US | disclosed |
| WO-2013101477-A1 | CURABLE POLYSILOXANE COATING COMPOSITION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20130158292-A1 | METHOD FOR PRODUCING METHIONINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-20 | — | — | US | disclosed |
| US-20130150611-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-06-13 | — | — | US | disclosed |
| US-6838489-B2 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | CYMETECH, LLC (US) | 2005-01-04 | — | — | US | disclosed |
| EP-1372844-A1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | California Institute of Technology (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003097562-A2 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-07-31 | — | — | US | disclosed |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | STERLING JA, L.C. | 2003-05-01 | — | — | US | disclosed |
| WO-2002076613-A1 | HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158292-A1 | METHOD FOR PRODUCING METHIONINE | MTR, MSMO1, MGMT | ALDH1A1 113/4885NPSR1 4175/4885POLB 214/4885 |
| US-20030144437-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | NQO1, NIT2, ALOX5 | ALDH1A1 1236/4885NPSR1 2433/4885POLB 498/4885 |
| US-20130150611-A1 | PROCESS FOR PRODUCING CARBOXYLIC ACID ESTER | ADH5, ADH1A, ADH1C | ALDH1A1 33/4885NPSR1 1920/4885POLB 2095/4885 |
| US-20030083445-A1 | High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor | NQO1, NIT2, ALOX5 | ALDH1A1 1236/4885NPSR1 2433/4885POLB 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.